These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26692039)

  • 21. [Raynaud's phenomenon: clinical aspects of the disease].
    Konychev AV; Koreshkina TA; Kokorin KV; Kaiukov AV
    Vestn Khir Im I I Grek; 2001; 160(2):118-22. PubMed ID: 11496483
    [No Abstract]   [Full Text] [Related]  

  • 22. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of botulinum toxin in vasospastic disorders of the hand.
    Neumeister MW
    Hand Clin; 2015 Feb; 31(1):23-37. PubMed ID: 25455354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 26. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
    Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
    Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Raynaud's phenomenon].
    Ratner GL; Slutsker GE
    Khirurgiia (Mosk); 1991 Jun; (6):36-40. PubMed ID: 1770734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
    Zulian F; Corona F; Gerloni V; Falcini F; Buoncompagni A; Scarazatti M; Martini G; Zacchello F
    Rheumatology (Oxford); 2004 Feb; 43(2):229-33. PubMed ID: 12923288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding, assessing and treating Raynaud's phenomenon.
    Boin F; Wigley FM
    Curr Opin Rheumatol; 2005 Nov; 17(6):752-60. PubMed ID: 16224254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasospasmolytic therapy in patients with SSC.
    Jünger M; Schlez A; Klyscz T; Steins A; Hahn M
    Adv Exp Med Biol; 1999; 455():305-7. PubMed ID: 10599360
    [No Abstract]   [Full Text] [Related]  

  • 34. [Raynaud's disease and phenomenon].
    Vilardell Tarrés M
    Med Clin (Barc); 1983 Dec; 81(18):808-10. PubMed ID: 6656450
    [No Abstract]   [Full Text] [Related]  

  • 35. Iloprost treatment of finger gangrene in a patient with Raynaud's syndrome.
    Levy Y; Sherer Y; Shoenfeld Y
    Isr Med Assoc J; 2000 Dec; 2(12):960-1. PubMed ID: 11344792
    [No Abstract]   [Full Text] [Related]  

  • 36. Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline.
    Gschwandtner ME; Koppensteiner R; Maca T; Minar E; Schneider B; Schnürer G; Ehringer H
    Microvasc Res; 1996 Jan; 51(1):29-38. PubMed ID: 8812752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.
    Watson HR; Belcher G
    Ann Rheum Dis; 1991 Jun; 50(6):359-61. PubMed ID: 1711834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine].
    De Broucker T; Lhote F
    Ann Med Interne (Paris); 2000 Sep; 151(5):424-5. PubMed ID: 11033481
    [No Abstract]   [Full Text] [Related]  

  • 39. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis.
    Zardi EM; Picardi A; Ambrosino G; Fazio VM; Dobrina A; Frego M; Afeltra A; Lumachi F
    In Vivo; 2006; 20(3):377-80. PubMed ID: 16724674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
    Gross R; Galus K; Zajac S; Jedrasik M
    Wiad Lek; 2002; 55(1-2):29-34. PubMed ID: 12043312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.